TFP

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN)

Retrieved on: 
Martedì, Settembre 7, 2021

Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.

Key Points: 
  • Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.
  • Its most advanced product candidate is Vicineum (VB4-845), a locally administered TFP developed as a treatment of bacillus Calmette-Gurin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • Sesen Bio reported preliminary efficacy data from its ongoing Phase 3 clinical trial for Vicineum, the VISTA trial, in August 2019.
  • On August 13, 2021, Sesen Bio announced that the FDA declined to approve its BLA for Vicineum in its current form.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN)

Retrieved on: 
Venerdì, Agosto 27, 2021
Company, BCG, NMIBC, Lists of schools in England, Therapy, STAT, VISTA, GLOBE, CMC, GPM, Court, Food, Liver failure, Health, Time, TFP, Hepatotoxicity, Clinical trial, NASDAQ, Safety, News, Toxicity, Suite, Bacillus, Defendant, FDA, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicine, Medical device, Dietary supplement, Pharmaceutical industry, Chemical

Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.

Key Points: 
  • Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.
  • Its most advanced product candidate is Vicineum (VB4-845), a locally administered TFP developed as a treatment of bacillus Calmette-Gurin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • Sesen Bio reported preliminary efficacy data from its ongoing Phase 3 clinical trial for Vicineum, the VISTA trial, in August 2019.
  • On August 13, 2021, Sesen Bio announced that the FDA declined to approve its BLA for Vicineum in its current form.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN)

Retrieved on: 
Martedì, Agosto 24, 2021
Legal, Professional Services, Company, BCG, NMIBC, Lists of schools in England, Therapy, Law, STAT, VISTA, CMC, Court, Food, Liver failure, Health, Time, TFP, Hepatotoxicity, Telephone, Clinical trial, NASDAQ, Safety, News, Toxicity, Suite, Bacillus, Defendant, FDA, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicine, Dietary supplement, Pharmaceutical industry, Chemical, Medical device

Investors suffering losses on their Sesen Bio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Sesen Bio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.
  • Sesen Bio reported preliminary efficacy data from its ongoing Phase 3 clinical trial for Vicineum, the VISTA trial, in August 2019.
  • On August 13, 2021, Sesen Bio announced that the FDA declined to approve its BLA for Vicineum in its current form.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sesen Bio, Inc. (SESN)

Retrieved on: 
Lunedì, Agosto 23, 2021
Legal, Professional Services, Company, BCG, NMIBC, Lists of schools in England, Therapy, STAT, VISTA, CMC, GPM, Court, Food, Liver failure, Health, Time, TFP, Hepatotoxicity, Clinical trial, NASDAQ, Safety, News, Toxicity, Suite, Bacillus, Defendant, FDA, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicine, Medical device, Dietary supplement, Pharmaceutical industry, Chemical

Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.

Key Points: 
  • Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.
  • Its most advanced product candidate is Vicineum (VB4-845), a locally administered TFP developed as a treatment of bacillus Calmette-Gurin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • Sesen Bio reported preliminary efficacy data from its ongoing Phase 3 clinical trial for Vicineum, the VISTA trial, in August 2019.
  • On August 13, 2021, Sesen Bio announced that the FDA declined to approve its BLA for Vicineum in its current form.

SESN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Sesen Bio, Inc.

Retrieved on: 
Venerdì, Agosto 20, 2021
Legal, Professional Services, Company, BCG, NMIBC, Securities Exchange Act of 1934, Lists of schools in England, Therapy, STAT, VISTA, CMC, GPM, Court, Person, Food, Liver failure, Health, Time, TFP, Hepatotoxicity, Clinical trial, NASDAQ, Safety, District court, News, Toxicity, Suite, Bacillus, Defendant, FDA, BLA, California, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicine, Pharmaceutical industry, Dietary supplement, Chemical, Medical device

Glancy Prongay & Murray LLP (GPM), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Bibb v. Sesen Bio, Inc.,et al., (Case No.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Bibb v. Sesen Bio, Inc.,et al., (Case No.
  • 21-cv-7025) on behalf of persons and entities that purchased or otherwise acquired Sesen Bio, Inc. (Sesen Bio or the Company) (NASDAQ: SESN ) securities between December 21, 2020 and August 17, 2021, inclusive (the Class Period).
  • Sesen Bio is a late-stage clinical company that purports to advance targeted fusion protein (TFP) therapeutics for cancer treatments.
  • Sesen Bio reported preliminary efficacy data from its ongoing Phase 3 clinical trial for Vicineum, the VISTA trial, in August 2019.